Navigation Links
Bionovo Announces 2011 Plan of Action on MF101 (Menerba™)
Date:2/10/2011

EMERYVILLE, Calif., Feb. 10, 2011 /PRNewswire/ -- Bionovo, Inc. (Nasdaq: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today articulated for investors the Company's plan of action for 2011 in the development of MF101 (Menerba™). The company also updated its investor information, available on the company's website.

"Having positive clinical and non-clinical data to date, regulatory clarity on requirements from the FDA and the EMA, we can confidently proceed in advancing Menerba into pivotal clinical testing," commented Dr. Isaac Cohen, chairman and chief executive officer of Bionovo, Inc. "Our recent successful financing was an additional validation for Menerba's future development toward commercialization. I look forward to concentrating on executing the business plan and proving the validity of our novel drug development process."

The Company's announced activities and milestones during 2011, based on current plans and progress, include:Manufacture of drug material at higher potency for clinical and non-clinical testing.

  Early first quarter.Conduct a 40 patient, 28-day "tolerability" trial at higher doses planned for later studies.

  Late first quarter, early second quarter.Non-clinical study for toxicity in rodents.

  Late first quarter, early second quarter.Manufacture of clinical material for Phase 3 study, using FDA-approved commercial process.

  Second quarter.Complete contracts, IRB approval and training at U.S. clinical sites for the Phase 3 study.

  First and second quarter.Initiate patient recruitment and screening in the Phase 3 study.

  End of the second quarter.Initiate dosing in the Phase 3 study.

  Early in the third quarter.Data Safety Monitoring Board interim revie
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
2. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
3. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
4. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
5. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
8. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
9. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
10. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
11. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... BioCorRx, Inc. ( BICX ) ... a healthcare solutions organization, which focuses solely on addiction treatment; ... the U.S. alone. The Company created a unique treatment program ... compounded form for outpatient surgical implantation. The Company has exclusive ... New Zealand ) to the specially formulated Naltrexone implant. ...
(Date:3/27/2015)... , March 27, 2015 Levi & Korsinsky ... Inc. (NASDAQ: OHRP ) concerning possible violations of ... by the Company in connection with its study of ... http://zlk.9nl.com/ohr-pharmaceutical-ohrp or contact Joseph E. Levi, ... or by telephone at (212) 363-7500, toll-free: (877) 363-5972. ...
(Date:3/27/2015)... 27, 2015 /CNW Telbec/ - Russell Williams , ... Companies (Rx&D), welcomes the 2015-2016 Quebec Budget, noting the ... on the biopharmaceutical industry. However, the association is concerned ... "We commend the government,s intent to strive for a ... to promote Quebec,s economic development ...
Breaking Medicine Technology:Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3
... 11, 2008, the Joint Advisory Committees of the ... the Drug Safety & Risk Management Advisory Committee, ... Advisory Committee - completed a review of the ... beta-agonists (LABAs). The committees concluded that the benefits ...
... JERSEY CITY, New Jersey and PHILADELPHIA, December 11, ... microRNA-based molecular diagnostics, announced today the,commercial availability of ... now commercially available through Rosetta Genomics,CLIA-certified lab in ... To order the test, physicians may contact 1-888-522-7971, ...
Cached Medicine Technology:AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R) 2AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R) 3AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R) 4Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 2Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 3Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 4Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 5
(Date:3/29/2015)... Aliso Viejo, California (PRWEB) March 29, 2015 ... have revealed a new transition from Pixel Film Studios, ... 12 sports transitions made exclusively for Final Cut Pro ... “We’ve given our users the tools needed to effortlessly ... Film Studios introduces TranSports, a new and uniquely styled ...
(Date:3/28/2015)... AZ. (PRWEB) March 28, 2015 Could ... to a new study by researchers at ... , Produced with the support of the Coffee and ... journal Molecular Psychiatry this past fall, the study—one of ... meta-analysis of genomic data from more than 120,000 regular ...
(Date:3/28/2015)... California-based leading wig brand UniWigs has prepared a mysterious ... the Easter Holidays from today until April 6th. There ... Day. , As the winter fades and spring approaches, ... with religious origins to countries in Europe and the ... best wig provider, UniWigs, would like to offer a ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Pitching speed, player’s ... history of shoulder and elbow injuries, according to new research ... ( AOSSM ) Specialty Day. , “Our findings indicate that ... 20% increase in likelihood of a history of injury, a ... a 12% increase likelihood of a history of injury, and ...
(Date:3/28/2015)... NC (PRWEB) March 28, 2015 Genomic ... with peritoneal mesothelioma, revealing, for the first time, key ... Click here to read the newly posted story ... at the University of British Columbia, the British Columbia ... genome mapping to reveal underlying molecular alterations and mutations ...
Breaking Medicine News(10 mins):Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2
... loses a chunk of its tail fin, it’ll grow back ... can replace surprisingly complex body parts. A tail fin, for ... very intricate structure. It is the fish version of an ... re-grow missing tails and other appendages has fascinated veterinary and ...
... infrastructure and health facilities has revealed that 14 inmates have ... These deaths are believed to have resulted from treatment errors ... been reported that the jail infrastructure lacks adequate doctors, nurses ... for medical conditions ranging from hernia to heart disease. ...
... Research Institute, have identified a sensor that identifies glucose levels. ... It acts like a switch that increases or decreases the ... it helps to convert glucose into fat for the purpose ... X Receptor. Its dual function makes it a potential site ...
... prominently weaker and are at a risk of getting fractured ... from this disease in the U.K. Women suffer from ... drugs used to treat osteoporosis., This group of drugs plays ... menopausal age. Such women face the risk of fractures due ...
... children have reportedly died from malnutrition in Madhya Pradesh's ... a deep-rooted problem afflicting over 80,000 underprivileged children in ... village died Sunday, two-year-old Chhottu died Dec 20 though ... care of him, the activists said., ,"Both deaths ...
... cracker when she was 14 months old that left her ... peanut is enough to trigger an allergic reaction in people ... 4 1/2, in a landmark experiment that set to discover-'Could ... eventually train children's bodies to overcome severe food allergies?' ...
Cached Medicine News:Health News:Regrowth of Zebrafish's Tail Fin may Offer Clues for Treating Human Injuries 2Health News:Regrowth of Zebrafish's Tail Fin may Offer Clues for Treating Human Injuries 3Health News:Glucose Sensor That Controls Glucose Metabolism Identified 2Health News:Optimum Period is Five Years to Treat Osteoporosis: Study 2Health News:Malnutrition Kills Two Kids In Madhya Pradesh 2Health News:Is Your Child Allergic To Peanuts? 2
Diagnose dry eye, assess the effectiveness of permanent punctal occlusion, collagen - dissolvable in 3-5 days, all are 2 mm long. Sterile...
The Multi-Purpose Stand Magnifier is the most versatile stand magnifier. The stand has multiple configurations allowing for all situations where hands-free magnification is needed....
... The aplanatic lens is made ... lens system consisting of two ... clearly defined, distortion-free image. This ... for patients with macular degeneration ...
... Sheets are commonly used for orbital ... The thinner 0.4 mm sheet was ... greater flexibility and to provide a ... the orbit. It is ideally suited ...
Medicine Products: